Skip to main content

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Editor's Choice

Mediterranean diet linked to reduced mortality in cancer survivors

Greater adherence to a Mediterranean diet is associated with a reduced risk for all-cause and cardiovascular mortality in cancer survivors.

SGLT2 inhibitors for cancer therapy-related cardiotoxicity?

SGLT2 inhibitors, initially developed for treating diabetes, have transformed the management of heart failure and CKD. Could they also play a role in preventing cardiotoxicity induced by cancer therapies?

Advances in therapy for non-melanoma skin cancers

Open Access Skin Cancer Review

The incidence of non-melanoma skin cancer continues to rise. Learn about the latest approved and emerging systemic therapies for locally advanced and metastatic disease.

Hodgkin’s lymphoma masquerading as ocular inflammation

Open Access Hodgkin Lymphoma Case Study

A 17-year-old presented with non-necrotizing scleritis, anterior uveitis, vitritis, yellowish chorioretinal lesions, papillitis, and vasculitis. Would you consider Hodgkin’s lymphoma in the differential diagnosis?

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Lung Cancer Clinical Trial Summary

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case Studies

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Hodgkin’s lymphoma masquerading as ocular inflammation

Open Access Hodgkin Lymphoma Case Study

A 17-year-old presented with non-necrotizing scleritis, anterior uveitis, vitritis, yellowish chorioretinal lesions, papillitis, and vasculitis. Would you consider Hodgkin’s lymphoma in the differential diagnosis?

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe

Current Reviews

Advances in biology, diagnosis and treatment of DLBCL

Open Access Diffuse Large B-Cell Lymphoma Review Article

Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) …

Patient-Centered Management of Brain Tumor-Related Epilepsy

Epilepsy Review

Brain-tumor related epilepsy (BTRE) is a heterogenous syndrome associated with primary and metastatic brain tumors, accounting for 6–10% of all cases of epilepsy [ 1 ], with an average annual age-adjusted incidence rate of 24.71 per 100,000 [ 2 ].

Pharmacological insights and role of bufalin (bufadienolides) in inflammation modulation: a narrative review

Bufadienolides, specifically bufalin, have garnered attention for their potential therapeutic application in modulating inflammatory pathways. Bufalin is derived from toad venom and exhibits promising anti-inflammatory properties. Its …

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis

Breast Cancer REVIEW ARTICLE

Breast cancer remains the most prevalent cancer type and the primary cause of cancer-related deaths among women worldwide [ 1 ]. The latest global cancer statistics from 2022 reveal a shift where female breast cancer has surpassed lung cancer …

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine

CME & eLearning

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME
SPONSORED

Webinar

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK. 

Sponsored by:
  • Novartis Pharma AG
Developed by: Springer Healthcare

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

Further Reading

Breast density effect on the sensitivity of digital screening mammography in a UK cohort

Open Access Mammography Breast

Breast cancer is one of the most common forms of cancer and early-stage diagnosis leads to better survival [ 1 ]. Population screening programmes aim to detect cancer early and reduce mortality. The UK National Health Service Breast Screening …

Advances in biology, diagnosis and treatment of DLBCL

Open Access Diffuse Large B-Cell Lymphoma Review Article

Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) …

Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer

Open Access Breast Cancer Original Article

Breast cancer is one of the most common malignant diseases worldwide and was the most common cancer among women in 2020 [ 1 ]. Among Japanese women, breast cancer is the most frequently diagnosed cancer, with 97,142 cases and 14,650 deaths reported …

Related topics

Hodgkin’s lymphoma masquerading as ocular inflammation

Open Access Hodgkin Lymphoma Case Study

A 17-year-old presented with non-necrotizing scleritis, anterior uveitis, vitritis, yellowish chorioretinal lesions, papillitis, and vasculitis. Would you consider Hodgkin’s lymphoma in the differential diagnosis?

Read more

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Read more